OpenURL Connection Search

Select item for more details and to access through your institution.

The risk of secondary progressive multiple sclerosis is geographically determined but modifiable.
Published in:
Brain: A Journal of Neurology, 2023, v. 146, n. 11, p. 4633, doi. 10.1093/brain/awad218
By:
- Sharmin, Sifat;
- Roos, Izanne;
- Simpson-Yap, Steve;
- Malpas, Charles;
- Sánchez, Marina M;
- Ozakbas, Serkan;
- Horakova, Dana;
- Havrdova, Eva K;
- Patti, Francesco;
- Alroughani, Raed;
- Izquierdo, Guillermo;
- Eichau, Sara;
- Boz, Cavit;
- Zakaria, Magd;
- Onofrj, Marco;
- Lugaresi, Alessandra;
- Weinstock-Guttman, Bianca;
- Prat, Alexandre;
- Girard, Marc;
- Duquette, Pierre
Publication type:
Article
Delay from treatment start to full effect of immunotherapies for multiple sclerosis.
Published in:
2020
By:
- Roos, Izanne;
- Leray, Emmanuelle;
- Frascoli, Federico;
- Casey, Romain;
- Brown, J William L;
- Horakova, Dana;
- Havrdova, Eva K;
- Trojano, Maria;
- Patti, Francesco;
- Izquierdo, Guillermo;
- Eichau, Sara;
- Onofrj, Marco;
- Lugaresi, Alessandra;
- Prat, Alexandre;
- Girard, Marc;
- Grammond, Pierre;
- Sola, Patrizia;
- Ferraro, Diana;
- Ozakbas, Serkan;
- Bergamaschi, Roberto
Publication type:
journal article
Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies.
Published in:
Multiple Sclerosis Journal - Experimental, Translational & Clinical, 2023, v. 9, n. 1, p. 1, doi. 10.1177/20552173221142741
By:
- Dayan, Colin M.;
- Lecumberri, Beatriz;
- Muller, Ilaria;
- Ganesananthan, Sashiananthan;
- Hunter, Samuel F.;
- Selmaj, Krzysztof W.;
- Hartung, Hans-Peter;
- Havrdova, Eva K.;
- LaGanke, Christopher C.;
- Ziemssen, Tjalf;
- Van Wijmeersch, Bart;
- Meuth, Sven G.;
- Margolin, David H.;
- Poole, Elizabeth M.;
- Baker, Darren P.;
- Senior, Peter A.
Publication type:
Article
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
Published in:
Multiple Sclerosis Journal, 2022, v. 28, n. 12, p. 1944, doi. 10.1177/13524585221102584
By:
- Cree, Bruce AC;
- Selmaj, Krzysztof W;
- Steinman, Lawrence;
- Comi, Giancarlo;
- Bar-Or, Amit;
- Arnold, Douglas L;
- Hartung, Hans-Peter;
- Montalbán, Xavier;
- Havrdová, Eva K;
- Sheffield, James K;
- Minton, Neil;
- Cheng, Chun-Yen;
- Silva, Diego;
- Kappos, Ludwig;
- Cohen, Jeffrey A
Publication type:
Article
Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.
Published in:
Multiple Sclerosis Journal, 2019, v. 25, n. 9, p. 1255, doi. 10.1177/1352458518789884
By:
- Cohen, Jeffrey A;
- Comi, Giancarlo;
- Arnold, Douglas L;
- Bar-Or, Amit;
- Selmaj, Krzysztof W;
- Steinman, Lawrence;
- Havrdová, Eva K;
- Cree, Bruce AC;
- Montalbán, Xavier;
- Hartung, Hans-Peter;
- Huang, Vivian;
- Frohna, Paul;
- Skolnick, Brett E;
- Kappos, Ludwig
Publication type:
Article
Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.
Published in:
JAMA Neurology, 2021, v. 78, n. 5, p. 558, doi. 10.1001/jamaneurol.2021.0405
By:
- Kappos, Ludwig;
- Fox, Robert J.;
- Burcklen, Michel;
- Freedman, Mark S.;
- Havrdová, Eva K.;
- Hennessy, Brian;
- Hohlfeld, Reinhard;
- Lublin, Fred;
- Montalban, Xavier;
- Pozzilli, Carlo;
- Scherz, Tatiana;
- D'Ambrosio, Daniele;
- Linscheid, Philippe;
- Vaclavkova, Andrea;
- Pirozek-Lawniczek, Magdalena;
- Kracker, Hilke;
- Sprenger, Till
Publication type:
Article

Found: 6

The risk of secondary progressive multiple sclerosis is geographically determined but modifiable.

Delay from treatment start to full effect of immunotherapies for multiple sclerosis.

Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies.

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.

Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.